India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), is implementing one of the most ambitious regulatory overhauls in its history. In a series of coordinated actions between February and June 2026, CDSCO has announced plans to outsource Good Manufacturing Practices (GMP) audits to certified third-party agencies, build a 1,500-strong scientific cadre, tightened safety reporting timelines for new drugs, and flagged over 160 medicines as “not of standard quality” in a single month. These developments signal a decisive shift toward regulatory rigor that will reshape India’s generic medicine landscape for international buyers.
🇮🇳 CDSCO to Outsource GMP Audits to QCI-Certified Agencies
In February 2026, CDSCO announced a landmark decision to outsource GMP and Good Clinical Practice (GCP) audits to agencies certified by the Quality Council of India (QCI) — as reported by IndiaMedToday, ETPharma, and Business Standard. This move is designed to address long-standing capacity constraints at CDSCO, where a limited number of inspectors has struggled to keep pace with India’s vast pharmaceutical manufacturing network of over 10,500 WHO-GMP compliant facilities.
By leveraging QCI-certified audit agencies, CDSCO aims to increase the frequency and depth of manufacturing site inspections without compromising technical rigor. For international buyers of Indian generic medicines, this means greater assurance that the products they import have been manufactured in facilities that meet globally recognized quality standards.
👨🔬 Building a 1,500-Strong Scientific Cadre
Alongside the audit outsourcing plan, CDSCO is recruiting approximately 1,500 scientific experts to deepen its technical review capacity. As reported by Business Standard (February 2026), these experts will be responsible for reviewing drug applications, evaluating clinical trial data, and strengthening the scientific rigor of CDSCO’s regulatory decisions.
This expansion addresses a key criticism from global regulators, including the USFDA and WHO, who have previously flagged CDSCO’s limited technical manpower as a bottleneck. A larger scientific cadre enables faster application processing without sacrificing review quality — a critical factor as India positions itself as the “Pharmacy of the World.”
📅 PSUR Timeline Shift: Safety Reports Now from Launch Date
In a separate directive issued in May 2026, CDSCO instructed all pharmaceutical manufacturers and importers to submit Periodic Safety Update Reports (PSURs) for new drugs from the actual launch date rather than the approval date. As reported by The Economic Times and Hindustan Times, the regulator noted that using approval dates instead of marketing dates results in the loss of “valuable safety insights” critical for monitoring adverse effects.
The advisory, communicated through the SUGAM portal, establishes a deferred timeline that ensures safety data collection begins the moment a product reaches patients — not months earlier when it was approved but not yet marketed. This reform aligns India’s pharmacovigilance practices with international standards followed by the USFDA and European Medicines Agency (EMA).
⚠️ 168 Medicines Flagged as “Not of Standard Quality” in March 2026
Further demonstrating its commitment to quality enforcement, CDSCO flagged 168 medicines as “not of standard quality” (NSQ) in March 2026 alone, as reported by ETV Bharat. The list spans multiple therapeutic categories and includes products from various manufacturers across India.
While the NSQ rate relative to India’s total pharmaceutical output remains low (well under 1% of total batches tested), the transparency of this disclosure is significant. International buyers can use CDSCO’s public NSQ alerts as a due diligence tool when selecting suppliers. The regulator’s willingness to publish specific findings — including batch numbers, manufacturer names, and reasons for failure — enhances trust in India’s regulatory framework.
🔍 What This Means for International Buyers
These four developments represent a coordinated effort by CDSCO to modernize India’s drug regulatory framework. For international buyers, distributors, and healthcare providers sourcing generic medicines from India, the implications are overwhelmingly positive:
- Stronger quality assurance: Outsourced GMP audits to QCI-certified agencies will increase the frequency and rigor of manufacturing site inspections, reducing the risk of substandard products entering export supply chains.
- Faster approvals, same rigor: The expanded scientific cadre will process drug applications more efficiently, meaning faster market access for new generic products without compromising safety reviews.
- Better pharmacovigilance: PSURs tied to launch dates rather than approval dates mean safety signals are detected earlier, benefiting patients worldwide who rely on Indian generics.
- Transparent quality data: Public NSQ alerts provide buyers with actionable intelligence for supplier due diligence — a resource that sophisticated importers can incorporate into their vendor qualification processes.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- IndiaMedToday — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre In Major Regulatory Overhaul” (February 2026)
- ETPharma — “CDSCO to outsource GMP audits; add 1,500 experts to strengthen scientific capacity” (February 2026)
- Business Standard — “CDSCO tightens quality net with audits, scientific cadre overhaul” (February 2026)
- The Economic Times — “Drugmakers must report safety data from launch date, not approval date: CDSCO” (May 2026)
- Hindustan Times — “Drug regulator asks firms to file safety reports from actual launch date of new drugs” (May 2026)
- drugscontrol.org — “CDSCO Issues Advisory: PSUR Submissions for New Drugs via SUGAM Portal” (May 2026)
- ETV Bharat — “CDSCO Flags 168 Medicines ‘Not Of Standard Quality’ In March 2026” (May 2026)
- NDTV — “Central Drugs Body Revamps Testing Permissions To Fast-Track Drug Approvals in India” (February 2026)
For more information, contact IMSDA at contact@indiamedicine.org.